PL373394A1 - Bicykliczne modulatory funkcji receptorów androgenowych - Google Patents

Bicykliczne modulatory funkcji receptorów androgenowych

Info

Publication number
PL373394A1
PL373394A1 PL03373394A PL37339403A PL373394A1 PL 373394 A1 PL373394 A1 PL 373394A1 PL 03373394 A PL03373394 A PL 03373394A PL 37339403 A PL37339403 A PL 37339403A PL 373394 A1 PL373394 A1 PL 373394A1
Authority
PL
Poland
Prior art keywords
androgen receptor
receptor function
bicyclic
modulators
bicyclic modulators
Prior art date
Application number
PL03373394A
Other languages
English (en)
Inventor
Chongqing Sun
Lawrence Hamann
David Augeri
Yingzhi Bi
Jeffrey Robl
Yan-Ting Huang
Tammy Wang
Ligaya Simpkins
Alexandra Holubec
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL373394A1 publication Critical patent/PL373394A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03373394A 2002-05-17 2003-05-15 Bicykliczne modulatory funkcji receptorów androgenowych PL373394A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38161602P 2002-05-17 2002-05-17
US40671102P 2002-08-29 2002-08-29

Publications (1)

Publication Number Publication Date
PL373394A1 true PL373394A1 (pl) 2005-08-22

Family

ID=29553541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373394A PL373394A1 (pl) 2002-05-17 2003-05-15 Bicykliczne modulatory funkcji receptorów androgenowych

Country Status (11)

Country Link
US (1) US20040019063A1 (pl)
EP (1) EP1506178A4 (pl)
JP (1) JP4637572B2 (pl)
AR (1) AR040030A1 (pl)
AU (1) AU2003234609A1 (pl)
IS (1) IS7527A (pl)
MY (1) MY139579A (pl)
PE (1) PE20040511A1 (pl)
PL (1) PL373394A1 (pl)
TW (1) TW200407324A (pl)
WO (1) WO2003096980A2 (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ES2310622T3 (es) * 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1546162B1 (en) 2002-09-20 2011-06-22 Promega Corporation Luminescence-based methods and probes for measuring cytochrome p450 activity
AU2003302084A1 (en) * 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
AU2003282780A1 (en) 2003-08-08 2005-03-07 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
NZ548209A (en) 2003-12-19 2009-07-31 Univ California Methods and materials for assessing prostate cancer thearapies
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) * 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
AU2005247405A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
EP1836202B1 (en) 2005-01-10 2016-12-21 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1935986B1 (en) 2005-05-31 2014-04-16 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
EP2272973B1 (en) 2005-05-31 2015-05-27 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
AU2006289281B2 (en) 2005-09-09 2012-05-17 KaNDy Therapeutics Ltd. Pyridine derivatives and their use in the treatment of psychotic disorders
JP5230448B2 (ja) * 2006-02-10 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーターとして有用な新イミダゾロピラゾール誘導体
JP5171649B2 (ja) * 2006-02-10 2013-03-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーターとして有用な、二環式イミダゾール又はチアジアゾール複素環
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
GB0610765D0 (en) * 2006-05-31 2006-07-12 Proskelia Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
RS57309B1 (sr) 2010-02-16 2018-08-31 Aragon Pharmaceuticals Inc Modulatori androgenih receptora i njihove upotrebe
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EA023970B1 (ru) * 2011-07-27 2016-07-29 Новартис Аг Производные пиразолина и их применение в качестве селективных модуляторов рецептора андрогена
JP2015006993A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 イミダゾロン誘導体
CN104169258B (zh) * 2011-12-22 2017-03-01 默克专利有限公司 用作激酶活性调节剂的新颖的杂环羧酰胺
MX371020B (es) 2012-09-26 2020-01-13 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP6703484B2 (ja) 2014-01-29 2020-06-03 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 細胞による取り込み測定のための、標識用試薬としての、キノンでマスクされたプローブ
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2017281038B2 (en) 2016-06-22 2021-09-09 Ellipses Pharma Ltd AR+ breast cancer treatment methods
JP6863832B2 (ja) * 2016-07-21 2021-04-21 日清ファルマ株式会社 筋萎縮抑制用組成物
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
EP4385985A1 (en) 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Heterocyclic derivative, and composition and pharmaceutical use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
NL6704169A (pl) * 1966-04-06 1967-10-09
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
JPS5195134A (pl) * 1975-02-10 1976-08-20
CA1076114A (en) * 1975-02-10 1980-04-22 Mitsubishi Chemical Industries Limited 1,5-alkylene-3-aryl hydantoin derivatives
JPS5933593B2 (ja) * 1976-01-01 1984-08-16 三菱化学株式会社 ヒダントイン又はチオヒダントインの誘導体
JPS55153763A (en) * 1979-05-21 1980-11-29 Kyowa Hakko Kogyo Co Ltd Modifier for citrus fruits
JPS57175189A (en) * 1981-04-21 1982-10-28 Kyowa Hakko Kogyo Co Ltd Benzothiazole derivative and its preparation
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
DE3809390A1 (de) * 1988-03-16 1989-09-28 Schering Ag Perhydro-imidazopyridine und -pyrroloimidazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
DE3827221A1 (de) * 1988-08-11 1990-02-15 Bayer Ag Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
HUT62296A (en) * 1990-12-18 1993-04-28 Sandoz Ag Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
EP0659187B1 (en) * 1992-09-10 2000-11-15 Degussa-Hüls Aktiengesellschaft Bicyclic imides as herbicides
IL107719A0 (en) * 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6310095B1 (en) * 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6329380B1 (en) * 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001007052A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
IL148932A0 (en) * 1999-10-20 2002-09-12 Tanabe Seiyaku Co INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
CA2393466C (en) * 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US6670386B2 (en) * 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion

Also Published As

Publication number Publication date
US20040019063A1 (en) 2004-01-29
AU2003234609A8 (en) 2003-12-02
AR040030A1 (es) 2005-03-09
JP4637572B2 (ja) 2011-02-23
TW200407324A (en) 2004-05-16
EP1506178A2 (en) 2005-02-16
WO2003096980A2 (en) 2003-11-27
AU2003234609A1 (en) 2003-12-02
EP1506178A4 (en) 2006-05-24
JP2005531555A (ja) 2005-10-20
IS7527A (is) 2004-11-12
MY139579A (en) 2009-10-30
WO2003096980A3 (en) 2004-10-21
PE20040511A1 (es) 2004-08-25

Similar Documents

Publication Publication Date Title
AU2003234609A8 (en) Bicyclic modulators of androgen receptor function
EP1414795A4 (en) BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
EP1722793A4 (en) BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION
TWI340738B (en) Modulators of the glucocorticoid receptor
EP1729763A4 (en) NEW BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD
EP1722790A4 (en) NEW BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD
EP1581217A4 (en) CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
IL163825A0 (en) Fluorinated 4-azasteroid derivatives as androgen receptor modulators
EP1501512A4 (en) 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
HK1079451A1 (en) Use of compounds that are effective as selective opiate receptor modulators
IL165792A0 (en) N-bridged selective androgen receptor modulators and methods of use thereof
EP1420796A4 (en) ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE
EP1567487A4 (en) OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2002367424A1 (en) Androgen receptor antagonists
EP1620453A4 (en) MODULATION OF GLUCAGON RECEPTOR EXPRESSION
AU2002353403A8 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
IL176215A0 (en) Modulators of muscarinic receptors
EP1562906A4 (en) SELECTIVE ANDROGEN RECEPTOR HETEROCYCLIC MODULATORS AND METHODS OF USE THEREOF
EP1558250A4 (en) GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
EP1558599A4 (en) HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY
AU2003256922A8 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003270066A8 (en) Modulators of angiogenesis
EP1567182A4 (en) PREVENTING DESENSIBILIZATION OF RECEPTORS
EP1622567A4 (en) ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
IL166069A0 (en) CCK-1 receptor modulators

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)